The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Predictive value of the antiangiogenic VEGF splice variant expression for bevacizumab efficacy in the phase III trial of bevacizumab and FOLFOX4 versus FOLFOX4 in previously treated patients with advanced colorectal cancer (ECOG E3200T2).
David O. Bates
Employment or Leadership Position - University of Bristol
Paul J. Catalano
No relevant relationships to disclose
Kirsty E. Symonds
No relevant relationships to disclose
Alexander H. R. Varey
No relevant relationships to disclose
Pramila Ramani
No relevant relationships to disclose
Peter James O'Dwyer
No relevant relationships to disclose
Bruce J. Giantonio
Honoraria - Roche/Genentech
Neal J. Meropol
Consultant or Advisory Role - AstraZeneca; Genentech; Genomic Health
Research Funding - Genomic Health
Al Bowen Benson
Consultant or Advisory Role - Genentech
Research Funding - Genentech
Steven J. Harper
No relevant relationships to disclose